On October 10, 2022 Alligator Bioscience AB (Nasdaq Stockholm: ATORX) reported that Mattias Levin, PhD, Sr Team Manager Antibody Engineering at Alligator Bioscience, will present at the 10th Annual Immuno-Oncology Summit being held in Boston and virtually, October 12-14 (Press release, Alligator Bioscience, OCT 10, 2022, View Source [SID1234621844]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Title: "Bispecific Tumor Antigen Conditional Agonistic Antibodies in Immuno-Oncology"
Date: Thursday 13 October 2022
Time: 10:30 am EDT / 4:30 pm CEST
The presentation will focus on Alligator’s Neo-X-Prime, a CD40-based bispecific platform with a dual mechanism of action that, in addition to CD40, targets tumor associated antigens (TAA) expressed at high densities. This enhances the uptake of tumor material by dendritic cells and increases effective neoantigen cross-priming of tumor specific T cells, resulting in increased anti-tumor efficacy. Neo-X-Prime bispecific antibodies address a key need in immune-oncology by increasing tumor specific T cells in the tumor microenvironment.

The presentation will highlight preclinical data and the medical opportunities in multiple cancer indications of ATOR-4066, Alligator’s preclinical first-in-class bispecific CD40 agonist.

Registration for the conference is open here.

The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on October 10, 2022.